DRugwatch BlogRSS 2.0

DRugwatch Blog

Contributor: Orestis Mavroudis-Chocholis

NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs. Read more.
Posted on: 10/9/2014 1:33:46 PM | with 0 comments


Contributors: Kirsha Naicker and Dan Roberts

HPV vaccinations were voted by ASCO this year to be one of the top five advances in modern oncology in the past 50 years. Read more.
Posted on: 10/8/2014 10:15:17 AM | with 0 comments


Contributor: Sehrish Rafique

Companies are now striving towards developing targeted therapies for advanced gastric cancer. Exploiting biomarkers is a dominant strategy and clinical data presented at the recent ESMO conference highlighted significant advances in the treatment of gastric cancer.
Read more.
Posted on: 10/7/2014 9:06:40 AM | with 0 comments


Contributor: Stefanie Hoffart

Between September 15 and 19, the European Association for the Study of Diabetes (EASD) meeting took place in Vienna, Austria, celebrating its 50th anniversary.
Read more.
Posted on: 10/1/2014 3:05:08 PM | with 0 comments


Contributors: Tim Blackstock and Stefanie Hoffart

Statins are one of the most commonly prescribed drugs, and Pfizer’s Lipitor (atorvastatin) still holds the record for the highest peak sales of any prescription drug. The general consensus of thought leaders in the field of lipid disorders and CVD prevention is that the benefits of statins outweigh the risks, although this applies more for secondary prevention that primary prevention.
Read more.
Posted on: 8/18/2014 1:07:35 PM | with 0 comments


Contributor: Chris Lewis

Faced with the onslaught of high-cost specialty drugs—a reality brought to the fore by the high-priced hepatitis C drug Sovaldi—many plan sponsors no doubt heaved a sigh of relief at the first U.S. filing for approval of a biosimilar last month. Read more.
Posted on: 8/13/2014 11:23:09 AM | with 0 comments


Contributor: Sangha Mitra

Last month, AstraZeneca took a major step to build up its respiratory franchise by striking a deal for the commercial rights to Almirall’s respiratory portfolio. The transaction, which is expected to complete by the end of 2014, could be worth up to $2.1 billion. It comprises an initial upfront payment of $875 million to Almirall and up to $1.22 billion in additional payments tied to performance, both regulatory and commercial, milestones.
Read more.
Posted on: 8/12/2014 4:17:19 PM | with 0 comments


Contributor: Jihan Khan

AMG-416 is being developed as a calcimimetic agent administered intravenously, which would be the first IV calcimimetic to the SHPT market. It is designed to bind and activate the calcium-sensing receptor on the parathyroid gland, thereby causing decreases in PTH.
Read more.
Posted on: 8/1/2014 11:23:09 AM | with 0 comments


  Contributer: Kate Keeping

 The moment that we (biosimilars enthusiasts) have all been waiting for has finally arrived! Sandoz has become the first company to disclose filing of a biosimilar application in the United States. On July 24, 2014, Sandoz announced that the FDA had accepted its application for approval of filgrastim (referencing Amgen’s Neupogen) via the previously unused biosimilar (aka 351[k]) pathway. Read more.
Posted on: 7/25/2014 10:27:16 AM | with 0 comments


Contributors: Graeme Green and Stefanie Hoffart

In May 2014, GlaxoSmithKline announced headline results of the Phase III SOLID-TIMI 52 outcomes trial that studied over 13,000 acute coronary syndrome (ACS) patients; the anti-inflammatory Lp-PLA2 inhibitor darapladib failed to significantly reduce the risk of cardiovascular death, myocardial infarction or urgent coronary revascularization for myocardial ischemia when added to standard of care.
Read more.
Posted on: 6/24/2014 12:43:03 PM | with 0 comments


Displaying results 1-10 (of 160)
 |<  < 1 2 3 4 5 6 7 8 9 10  >  >| 

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
Advancing the Treatment of TKI-refractory NSCLC
Post date:
10/9/2014 1:33:46 PM
Post Summary:
Contributor: Orestis Mavroudis-Chocholis

NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs.

Post title:
Realizing the Potential of HPV-associated Cancer Prevention
Post date:
10/8/2014 10:15:17 AM
Post Summary:
Contributors: Kirsha Naicker and Dan Roberts

HPV vaccinations were voted by ASCO this year to be one of the top five advances in modern oncology in the past 50 years.

Post title:
Gastric Cancer: The Ghosts of Past, Present and Future
Post date:
10/7/2014 9:06:40 AM
Post Summary:
Contributor: Sehrish Rafique

Companies are now striving towards developing targeted therapies for advanced gastric cancer. Exploiting biomarkers is a dominant strategy and clinical data presented at the recent ESMO conference highlighted significant advances in the treatment of gastric cancer.

Post title:
EASD 2014: SGLT-2 inhibitors, GLP-1 agonists, insulins, long-term study results, and speculations about triple combination therapies
Post date:
10/1/2014 3:05:08 PM
Post Summary:
Contributor: Stefanie Hoffart

Between September 15 and 19, the European Association for the Study of Diabetes (EASD) meeting took place in Vienna, Austria, celebrating its 50th anniversary.

Post title:
Statins: Add Them to the Drinking Water?
Post date:
8/18/2014 1:07:35 PM
Post Summary:
Contributors: Tim Blackstock and Stefanie Hoffart

Statins are one of the most commonly prescribed drugs, and Pfizer’s Lipitor (atorvastatin) still holds the record for the highest peak sales of any prescription drug. The general consensus of thought leaders in the field of lipid disorders and CVD prevention is that the benefits of statins outweigh the risks, although this applies more for secondary prevention that primary prevention.

Decision Resources Group brands include: